Lataa...
Long-term efficacy and safety of exemestane in the treatment of breast cancer
Exemestane, a steroidal aromatase inhibitor, is licensed for postmenopausal patients with estrogen receptor (ER)-positive breast cancer as second-line therapy in metastatic disease following antiestrogen failure and as part of sequential adjuvant therapy following initial tamoxifen. This study is a...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3616141/ https://ncbi.nlm.nih.gov/pubmed/23569364 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S42223 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|